Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Humacyte
company
About
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $175M
- Industries
- Biotechnology,Medical,Medical Device
- Founded date
- Jan 1, 2004
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$175M
Humacyte has raised a total of
$175M
in funding over 2 rounds. Their latest funding was raised on
Aug 27, 2021 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 27, 2021 | Post-IPO Equity | $175M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Humacyte is funded by 1 investors.
UBS O'Connor
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
UBS O'Connor
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
